A Danish database initiative was established in 2003 with the purpose of evaluating patients treated with teriparatide. After the introduction in 2006 of 184-PTH, these patients were also included. A total of 1494 patients from 19 centers were reported to the database, until closure in 2011. The reported patients correspond to a third of all patients in Denmark receiving anabolic treatment during this time period. With regard to age and sex the reported patients do not differ from the entire group of patients treated with teriparatide or 184-PTH. Almost 80 patients. of patients treated were having at least two vertebral fractures, while the remaining group had a single vertebral fracture in combination with a T-score <−3.0. Thirty-five patients. of the patients were reported to be treatment naïve, while 38% had suffered a vertebral fracture despite antiresorptive treatment. This pattern did not change over time.
Eighty-three patients. were treated with teriparatide, while 17 patients. received 184-PTH. The vast majority was treated for 18 months, since this was the maximum reimbursement period for the main part of the study. Comparing teriparatide and 184-PTH parallel patterns in changes in BMD of the spine and total hip were seen, with ~10 patients. increase at the lumbar spine and one patient. increase at the total hip. Identical responses were found in females and males, as well as in patients previously treated with bisphosphonates compared to treatment naïve. Side effects reported were few and equally distributed between the two treatments, except for hypercalcaemia that was more frequently reported in patients treated with 184-PTH. Only very few patients stopped treatment prematurely due to side effects.
With the use of voluntary clinical database additional information on how a new treatment is adopted by clinicians and how patients respond to treatment.
17 May 2014 - 20 May 2014